Allelic loss in breast cancer

Cancer Detection and Prevention

Volumn 26, Issue 6, 2002, Pages 426-434

  Miyakis, Spiros ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Breast cancer; Loss of heterozygosity; Oncogenes; Tumour suppressor genes

Indexed keywords

MICROSATELLITE DNA;

ALLELIC IMBALANCE; BREAST TUMOR; CHROMOSOME; FEMALE; FORECASTING; GENETICS; HETEROZYGOSITY LOSS; HUMAN; PATHOLOGY; REVIEW;

ALLELIC IMBALANCE; BREAST NEOPLASMS; CHROMOSOMES; FEMALE; FORECASTING; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS;

EID: 0036914915     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00128-9     Document Type: Review

References (94)

1. Modrich P. Mismatch repair, genetic stability and cancer. Science 1994;266:1959-60.
2. Dunning AM, Healey CS, Pharoah PD, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54.
3. Vos CB, ter Haar NT, Rosenberg C, et al. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 1999;81:1410-8.
4. Buerger H, Schmidt H, Beckmann A, et al. Genetic characterisation of invasive breast cancer: A comparison of CGH and PCR based multiplex microsatellite analysis. J Clin Pathol 2001;54:836-40.
5. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
6. Knudson AG. Mutation and cancer. Statistical study of retinoblastoma. Proc Nad Acad Sci USA 1971;68:820-3.
7. Cavanee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983;305:779-84.
8. Feuer EJ, Wun LM, Boring CC, et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892-7.
9. Parker SL, Tong T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1996;46:5-27.
10. Osborne RJ, Hamshere MG. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res 2000;60:3706-12.
11. Sourvinos G, Kiaris H, Tsikkinis A, et al. Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumour Biol 1997;18:157-66.
12. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
13. Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17q12-23. Lancet 1991;338:82-3.
14. Miki Y, Swenson J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
15. Neuhausen SL, Marshall CJ. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res 1994;54:6069-72.
16. Holt JT, Thompson ME, Szabo C, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996;12:298-302.
17. Thompson ME, Jensen RA, Obermiller PS, et al. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995;9:444-50.
18. Easton DF, Bishop DT, Ford D. et al. Breast cancer linkage consortium. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 1993;52:678-701.
19. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 1998;62:676-89.
20. Iau PT, MacMillan RD, Blamey RW. Germ line mutations associated with breast cancer susceptibility. Eur J Cancer 2001;37:300-21.
21. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62.
22. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
23. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-9.
24. Yang X, Lippman ME. BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat 1999;54:1-10.
25. Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002;359:1471-7.
26. Katsama A, Sourvinos G, Zachos G, et al. Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. Cancer Lett 2000;150:165-70.
27. Silva JM, Gonzalez R, Provencio M, et al. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Res Treat 1999;53:9-17.
28. Rio PG, Maurizis JC, Peffault de Latour M, et al. Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. Int J Cancer 1999;80:823-6.
29. Johnson SM, Shaw JA, Walker RA. Sporadic breast cancer in young women: Prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer 2002;98:205-9.
30. Sourvinos G, Spandidos DA. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun 1998;245:75-80.
31. Cleton-Jansen AM, Collins N, Lakhani SR, et al. Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer 1995;72:1241-4.
32. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
33. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
34. Eiriksdottir G, Johannesdottir G, Ingvarsson S, et al. Mapping loss of heterozygosity at chromosome 13q: Loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. Eur J Cancer 1998;34:2076-81.
35. Bieche I, Lidereau R. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinog 2000;29:151-8.
36. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
37. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
38. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002;4:70-6.
39. Saitoh S, Cunningham J, De Vries EM, et al. p53 gene mutations in breast cancers in midwestern US women: Null as well as missense-type mutations are associated with poor prognosis. Oncogene 1994;9:2869-75.
40. Gentile M, Bergman Jungestrom M, Olsen KE, et al. p53 and survival in early onset breast cancer: Analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer 1999;35:1202-7.
41. Querzoli P, Albonico G, di Iasio MG, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat 2001;66:135-42.
42. Seitz S, Poppe K, Fischer J, et al. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: Association with clinicopathological parameters. J Pathol 2001;194:318-26.
43. Cornelis RS, van Vliet M, Vos CB, et al. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 1994;54:4200-6.
44. Phelan CM, Borg A, Cuny M, et al. Consortium study on 1280 breast carcinomas: Allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 1998;58:1004-12.
45. Liscia DS, Morizio R, Venesio T, et al. Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene. Br J Cancer 1999;80:821-6.
46. Cousin P, Billotte J, Chaubert P, et al. Physical map of 17p13 and the genes adjacent to p53. Genomics 2000;63:60-8.
47. Wales MM, Biel MA, El-Deiry W, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995;1:570-7.
48. Fujii H, Biel MA, Zhou W, et al. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 1998;16:2159-64.
49. Luo L, Chen J, Du Q, et al. A region close to Tp53 shows LOH in familial breast cancer. Int J Mol Med 2002;9:405-9.
50. Bieche I, Champeme MH, Lidereau R. Loss and gain of distinct regions of chromosome 1q in primary breast cancer. Clin Cancer Res 1995;1:123-7.
51. Tsukamoto K, Ito N, Yoshimoto M, et al. Allelic loss on chromosome 1p is associated with progression and lymph node metastasis of primary breast carcinoma. Cancer 1998;82:317-22.
52. Bieche I, Khodja A, Lidereau R. Deletion mapping in breast tumor cell lines points to two distinct tumor-suppressor genes in the 1p32-pter region, one of deleted regions (1p36.2) being located within the consensus region of LOH in neuroblastoma. Oncol Rep 1998;5:267-72.
53. Utada Y, Emi M, Yoshimoto M, et al. Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer. Clin Cancer Res 2000;6:3193-8.
54. Ahomadegbe JC, Tourpin S, Kaghad M, et al. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers. Oncogene 2000;19:5413-8.
55. Dominguez G, Silva JM, Silva J, et al. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res Treat 2001;66:183-90.
56. Gaki V, Tsopanomichalou M, Sourvinos G, et al. Allelic loss in chromosomal region 1q21-23 in breast cancer is associated with peritumoral angiolymphatic invasion and extensive intraductal component. Eur J Surg Oncol 2000;26:455-60.
57. Gonzalez R, Silva JM, Dominguez G, et al. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: Pathological correlations. Br J Cancer 1999;81:503-9.
58. Borg A, Zhang QX, Olsson H, et al. Chromosome 1 alterations in breast cancer: Allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. Genes Chromosomes Cancer 1992;5:311-20.
59. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
60. Latif F, Tory K, Gnarra J, et al. Identification of the Von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
61. Matsumoto S, Kasumi F, Sakamoto G, et al. Detailed deletion mapping of chromosome arm 3p in breast cancers: A 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors. Genes Chromosomes Cancer 1997;20:268-74.
62. Sourvinos G, Miyakis S, Liloglou TL, et al. Von Hippel-Lindau tumour suppressor gene is not involved in sporadic human breast cancer. Tumour Biol 2001;22:131-6.
63. Maitra A, Wistuba II, Washington C, et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 2001;159:119-30.
64. Huiping C, Jonasson JG, Agnarsson BA, et al. Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer. Eur J Cancer 2000;36:1552-7.
65. Bergthorsson JT, Johannsdottir J, Jonasdottir A, et al. Chromosome imbalance at the 3p14 region in human breast tumours: High frequency in patients with inherited predisposition due to BRCA2. Eur J Cancer 1998;34:142-7.
66. Martinez A, Walker RA, Shaw JA, et al. Chromosome 3p allele loss in early invasive breast cancer: Detailed mapping and association with clinicopathological features. Mol Pathol 2001;54:300-6.
67. Lininger RA, Zhuang Z, Man Y, et al. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast. Mod Pathol 1999;12:1083-9.
68. Miyakis S, Sourvinos G, Liloglou TL, et al. The Von Hippel-Lindau (VHL) tumor-suppressor gene is not mutated in sporadic human colon adenocarcinomas. Int J Cancer 2000;88:503-5.
69. Huiping C, Sigurgeirsdottir JR, Jonasson JG, et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer 1999;81:1103-10.
70. Cleton-Jansen AM, Callen DF, Seshadri R, et al. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res 2001;61:1171-7.
71. Lininger RA, Park WS, Man YG, et al. LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. Hum Pathol 1998;29:1113-8.
72. Sigbjornsdottir BI, Ragnarsson G, Agnarsson BA, et al. Chromosome 8p alterations in sporadic and BRCA2 999de15 linked breast cancer. J Med Genet 2000;37:342-7.
73. Seitz S, Werner S, Fischer J, et al. Refined deletion mapping in sporadic breast cancer at chromosomal region 8p12-p21 and association with clinicopathological parameters. Eur J Cancer 2000;36:1507-13.
74. Yokota T, Yoshimoto M, Akiyama F, et al. Frequent multiplication of chromosomal region 8q24.1 associated with aggressive histologic types of breast cancers. Cancer Lett 1999;139:7-13.
75. Bose S, Wang SI, Terry MB, et al. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 1998;17:123-7.
76. Garcia JM, Silva JM, Dominguez G, et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 1999;57:237-43.
77. Freihoff D, Kempe A, Beste B, et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 1999;79:754-8.
78. Feilotter HE, Coulon V, McVeigh JL, et al. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 1999;79:718-23.
79. Winqvist R, Hampton GM, Mannermaa A, et al. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 1995;55:2660-4.
80. Laake K, Odegard A, Andersen TI, et al. Loss of heterozygosity at 11q23.1 in breast carcinomas: Indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer 1997;18:175-80.
81. Gentile M, Olsen K, Dufmats M, et al. Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: Association with poor survival. Br J Cancer 1999;80:843-9.
82. Laake K, Launonen V, Niederacher D, et al. Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study. Breast cancer somatic genetics consortium. Genes Chromosomes Cancer 1999;25:212-21.
83. Launonen V, Laake K, Huusko P, et al. European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: Relation to clinical variables. Breast cancer somatic genetics consortium. Br J Cancer 1999;80:879-82.
84. Moinfar F, Man YG, Bratthauer GL, et al. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (clinging ductal carcinoma in situ): A simulator of normal mammary epithelium. Cancer 2000;88:2072-81.
85. Selim AG, Ryan A, El-Ayat G, et al. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: Microdissection microsatellite analysis. J Pathol 2002;196:287-91.
86. Lichy JH, Dalbegue F, Zavar M, et al. Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest 2000;80:291-301.
87. Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002;196:280-6.
88. Hirano A, Emi M, Tsuneizumi M, et al. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 2001;7:876-82.
89. Li Z, Moore DH, Meng ZH, et al. Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. Cancer Res 2002;62:1000-3.
90. Hampl M, Hampl JA, Reiss G, et al. Loss of heterozygosity accumulation in primary breast carcinomas and additionally in corresponding distant metastases is associated with poor outcome. Clin Cancer Res 1999;5:1417-25.
91. Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000;60:3884-92.
92. Vos CB, ter Haar NT, Rosenberg C, et al. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 1999;81:1410-8.
93. Kollias J, Man S, Marafie M, et al. Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat 2000;64:241-51.
94. Chen X, Bonnefoi H, Diebold-Berger S, et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999;5:2297-303.